FDG PET/CT outperforms biopsy for detection of malignancy in lymphoma

May 17, 2013

The gold standard for the detection of bone marrow invasion of diffuse large B-cell lymphoma (DBLCL) is bone marrow biopsy (BMB). Researchers investigated a new approach with F-18 FDG PET/CT imaging to determine its efficacy and predictive value. The latter was found superior to biopsy in not only its sensitivity and accuracy, but also its ability to predict progression-free survival, according to a study published online May 14 in the Journal of Nuclear Medicine.

Louis Berthet, MD, a research scientist from the Centre Georges-Francois Leclerc in Dijon, France, and colleagues retrospectively compared F-18 FDG and bone marrow biopsy findings and performed a statistical analysis to evaluate best practice for DLBCL-related bone marrow cancer screening and restaging.